Abstract
We aimed to compare and evaluate the efficacies of a continuous regimen of intranasal salmon calcitonin (SCT) and two cyclic regimens (different cyclic regimens from previous studies) based on alternating 15 days or on 10 days consecutively per month for 1 year in the treatment of postmenopausal osteoporosis. We performed an open-label, prospective, randomized clinical trial. A total of 120 postmenopausal osteoporotic participants between 50 and 65 years old were randomly assigned to one of three treatment groups. Patients in group 1 (n=40) received continuously SCT nasal spray at a dose of 200 IU/day, plus continuously 500 mg/day elementary calcium and 0.25 μg/day 1-α hydroxyvitamin D3, for 1 year. Patients in group 2 (n=40) received cyclically SCT nasal spray at a dose of 200 IU/day on alternating 15 days per month, plus continuously 500 mg/day elementary calcium and 0.25 μg/day 1-α hydroxyvitamin D3, for 1 year. Patients in group 3 (n=40) received cyclically SCT nasal spray on 10 days consecutively per month (20 days/month rest), plus continuously 500 mg/day elementary calcium and 0.25 μg/day 1-α hydroxyvitamin D3, for 1 year. Data was evaluated by repeated analysis of variance (ANOVA). In addition, statistical differences between groups were assessed by the two-tailed Student’s t test. After 1 year of the study, seven patients from group 1, eight patients from group 2 and five patients from group 3 withdrew from the study. No patient discontinued the study because of adverse drug effects. There was a statistically-significant improvement in pain intensity VAS scores at the end of the year to baseline scores in all three groups (p<0.001). There was no significant difference in pain intensity VAS scores between groups at the end of the year (p>0.05). Lumbar and femur neck BMD scores improved significantly at the end of treatment in all three groups (p<0.05). There was no statistically-significant difference in BMD scores between groups at final (p>0.05). Urinary DPD/Cre levels decreased significantly in all three groups by the end of the year (p<0.05). There was no statistically-significant difference in urinary DPD/Cre final levels between groups (p>0.05). According to the results of the present study, consecutive 10 days therapy with SCT, which is the first in the literature to our knowledge, is as effective as the other two regimens in the treatmnent of osteoporosis. Both cyclic regimens in our study (alternating 15 days and 10 consecutive days each month for 1 year) do appear to offer some advantages, especially economically and clinically, as compared to continuous treatment.
Similar content being viewed by others
References
Munoz BY, Domingo AR, Minguella JF (2000) Calcitonin, osteoporosis treatment and prevention. Drugs of Today 36(Suppl D):13–25
Melton LJ, Chrichilles EA, Cooper C et al (1992) Perspective. How many women have osteoporosis. J Bone Miner Res 7:1005–1010
Khan A (2003) Advances in osteoporosis therapy 2003 update of practical guidelines. Can Fam Physician 49:441–7
Reid IR (2002) Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety. Expert Opin Drug Saf 1(1):93–107
Seeman E, Allen T (1989): Risk factors for osteoporosis. Aust N Z J Med 19:69–75
Consensus development conference (1993) Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646–650
Meunier PJ (1992) Calcitonin and bone diseases. Lancet 25(339):1065
Ryan PJ, Harrison R, Blake GM et al (1992) Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol 99:325–328
Overgaad K, Hansen MA, Jensen SB (1992) Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose response study. BMJ 5(305):556–561
Overgaad K, Lindsay R, Christiansen C (1995) Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of 2-year study. Clin Ther 17:660–665
Beck Jensen JE, Thamsborg G, Kollerup G et al (1995) Effect of nasal salmon calcitonin in established osteoporosis. Bone 16(Suppl):198S
Flicker L, Larkins RG, Hooper JL et al (1995) Nandrolone deaconate and intranasal calcitonin as therapy in established osteoporosis. Bone 16 (Suppl):164
Thamsborg G, Storm TL, Sykulsky R et al (1991) Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 48:302–307
Srivastava M, Deal C (2002) Osteoporosis in elderly: prevention and treatment. Clin Geriatr Med.18(3):529–555
Eichner SF, Lloyd KB, Timpe EM (2003) Comparing therapies for postmenopausal osteoporosis prevention and treatment. Ann Pharmacother 37(5):711–724
Abellan Perez M, Bayina Garcia FJ, Calabozo M et al (1995) Multicentre comparative study of synthetic salmon calcitonin administered nasally in the treatment of established postmenopausal osteoporosis. Ann Med Int 12:12–26
Gennari C, Agnusdei D, Camporeale A (1993) Effect of salmon calcitonin nasal spray on bone mass in patients with high turnover osteoporosis. Osteoporosis Int 3(Suppl 1):208–210
Gennari C, Agnusdei D, Camporeale A (1993) Long-term treatment with calcitonin in osteoporosis. Horm Metab Res 25:484–485
Munoz TM, Mezquita RP (2000) Calcitonin. Drugs of Today 36(Suppl D):1–11
Maini M, Bozzi M, Brignoli E et al (1995) Calcitonin nasal spray in osteoporosis: short and long-term effects of various treatment regimens. Minerva Med 86:121–127
Fioretti P, Gambacciani M, Taponeco F et al (1992) Effect of continuous and cyclic nasal calcitonin administration in ovariactomized women. Maturitas 15:225–232
Stuart L, Silverman SL, Chesnut C et al (1998) Salmon calcitonin nasal spray (NS-CT) reduces risk of vertebral fracture (VF) in established osteoporosis and has continuous efficacy with prolonged treatment: Accrued 5 year worldwide data of the PROOF study. 2nd joint meeting American Society Bone and Mineral Research Abstract, San Francisco
Takahashi S, Goldring S, Katz M (1995) Down-regulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 95:167–171
Gennari C (2002) Analgesic effect of calcitonin in osteoporosis. Bone 30(5):675–705
Lyritis GF, Tsakalatos N, Magiasis B et al (1991) Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double blind-placebo controlled study. Calcif Tissue Int 49:369–372
Pontiroli AE, Pajeta E, Scaglia L et al (1994). Analgesic effect of intranasal and intramuscular salmon calcitonin in postmenopausal osteoporosis: a double-blind, double-placebo study. Aging Clin Exp Res 6:459–463
Silverman SL, Azria M. (2002) The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 13(11):858–867
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tekeoğlu, İ., Adak, B., Budancamanak, M. et al. Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis. Rheumatol Int 26, 157–161 (2005). https://doi.org/10.1007/s00296-004-0549-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-004-0549-7